

Supplementary Material

Inclusion Criteria

1. Aged ≥ 18 years old
2. Subjects ≥ 1 year after sleeve gastrectomy (SG)
3. Able to understand written and spoken English
4. Able to give informed consent
5. Happy for their GP to be notified of their study participation

Exclusion criteria:

1. Use of any glucose-lowering medication (including insulin)
2. Adrenal insufficiency and/or substitution with glucocorticoids
3. $\text{eGFR} \leq 45 \text{ ml/min/1.73m}^2$
4. $\text{weight} \leq 50\text{kg}$
5. Recent active infection (an active infection will be any infection over the last 10 days)
6. Current use or history of treatment within 6 weeks with systemic glucocorticoids (oral or injectable) not including use of topical (e.g. eye drops or topical creams) or inhaled glucocorticoids
7. People with allergy or severe intolerance to the mixed meal tolerance test as assessed by the clinician (e.g., severe milk protein allergy, lactose and gluten intolerance)
8. People with allergy or intolerance to paracetamol or to nuts
9. Other bariatric procedure except of SG
10. Previous major revisional bariatric surgery (except of previous gastric band which has been removed)
11. $\text{Hb} < 100 \text{ g/L}$ at screening blood tests
12. $\text{HbA1C} \geq 6.5\%$ or $\geq 48 \text{ mmol/L}$ at screening blood tests
13. Currently pregnant or breastfeeding
14. Diagnosis of Type 1 Diabetes
15. Current diagnosis of Type 2 Diabetes (defined as $\text{HbA1C} \geq 6.5\%$ or $\geq 48 \text{ mmol/L}$ at screening blood tests or $\text{HbA1C} < 6.5\%$ or $< 48 \text{ mmol/L}$ at screening blood tests but on glucose lowering medications over last 3 months)
16. Patients with diagnosis of Epilepsy

17. Participating in another Clinical Trials of Investigational Medicinal Products (CTIMP) study within <1 month of screening
18. Having a formal previous diagnosis of postprandial hypoglycaemia
19. Currently on Metoclopramide, domperidone or colestyramine as they can affect paracetamol absorption as per SPC (Summary of Product Characteristics) for paracetamol.
20. Currently on acarbose, diazoxide, octreotide or other treatment for postprandial hypoglycaemia
21. Any concurrent condition, in the judgment of investigator and/ or GP practitioner, that could interfere with the safety and study conduct or interpretation of study results